Cecilia Tibery

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial”.

Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial

Nature Medicine(2025)10.1038/s41591-024-03361-4

N/A

0.954DataRank · unranked

41 citations

Geraldine O’Sullivan Coyne, Eva Dombi, Cecilia Tibery, William G. Herrick, Staci Martin +30 more

The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas

Neuro-Oncology Advances(2020)10.1093/noajnl/vdaa095

N/A

0DataRank · unranked

38 citations

Eva H. Baker, Andrea M. Gross, Patricia Whitcomb, Andrea Baldwin, Joanne Derdak +9 more

Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3612

N/A

0DataRank · unranked

24 citations

Andrea M. Gross, Eva Dombi, Cecilia Tibery, Amanda Carbonell, Naoko Takebe +13 more

Perceived transition readiness among adolescents and young adults with neurofibromatosis type 1 and plexiform neurofibromas: a cross-sectional descriptive study

Journal of Pediatric Psychology(2024)10.1093/jpepsy/jsae006

N/A

0DataRank · unranked

4 citations

Robin Lockridge, Kari Struemph, Mary Anne Toledo‐Tamula, Paige Little, Pamela L. Wolters +6 more